-transparent.png){kind=logo}
This paper outlines the chemical background to the selection of compounds likely to be clinically superior to the nitroimidazoles currently being evaluated in cancer therapy. The most important chemical properties to consider are electron affinity and lipophilicity, and the quantification and prediction of both these properties are considered. Examples are presented of the use of multiple regression analysis to evaluate the relative contribution of individual properties to the overall biological response.
Related Publications
P Wardman, and
E D Clarke, and
I R Flockhart, and
R G Wallace
January 1978,
Strahlentherapie. Sonderbande,
P Wardman, and
E D Clarke, and
I R Flockhart, and
R G Wallace
November 1979,
Radiology,
P Wardman, and
E D Clarke, and
I R Flockhart, and
R G Wallace
August 1980,
Journal of the National Medical Association,
P Wardman, and
E D Clarke, and
I R Flockhart, and
R G Wallace
June 1976,
The New England journal of medicine,
P Wardman, and
E D Clarke, and
I R Flockhart, and
R G Wallace
February 1985,
International journal of radiation oncology, biology, physics,
P Wardman, and
E D Clarke, and
I R Flockhart, and
R G Wallace
June 1981,
International journal of radiation oncology, biology, physics,
P Wardman, and
E D Clarke, and
I R Flockhart, and
R G Wallace
September 1988,
International journal of radiation oncology, biology, physics,
P Wardman, and
E D Clarke, and
I R Flockhart, and
R G Wallace
January 1980,
Cancer clinical trials,
P Wardman, and
E D Clarke, and
I R Flockhart, and
R G Wallace
January 1980,
Cancer clinical trials,
P Wardman, and
E D Clarke, and
I R Flockhart, and
R G Wallace
July 1983,
Radiation research,
